Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications

Noémi Zsíros, Péter Koncsos, Hajnalka Lorincz, I. Seres, Mónika Katkó, Anita Szentpéteri, Viktória E. Varga, Péter Fülöp, G. Paragh, M. Harangi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Myeloperoxidase (MPO), matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) were shown to contribute to atherogenesis, while human paraoxonase-1 (PON1) protects against oxidative stress. Although several studies investigated these biomarkers, their associations have not been completely clarified yet. We aimed to investigate these parameters in overweight hyperlipidemic, lipid-lowering therapy-naive patients (n = 167) with and without vascular complications. Design and methods: MPO, MMP-9 and TIMP-1 levels were measured by ELISA. PON1 activities were detected spectrophotometrically. PON1 phenotype was calculated by using a dual substrate method. Results: Patients with vascular complications (VC) had significantly higher MPO and TIMP-1 levels compared to those without (patients with no vascular complications; NVC) (728 (367.25-1177.90) mg/ml vs. 315.9 (176.05-687.40) mg/ml; p.

Original languageEnglish
JournalClinical Biochemistry
DOIs
Publication statusAccepted/In press - Dec 30 2015

Keywords

  • Hyperlipidemia
  • MMP-9
  • Myeloperoxidase
  • Obesity
  • Paraoxonase-1
  • TIMP-1

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Paraoxonase-1 arylesterase activity is an independent predictor of myeloperoxidase levels in overweight patients with or without cardiovascular complications'. Together they form a unique fingerprint.

  • Cite this